|
|
|
| Clinical study of Anlotinib combined with Irinotecan in the treatment of advanced extensive small cell lung cancer after Etoposide + Cisplatin regimen |
| PEI Xiufeng HE Chuan LI Xiaofeng ZHAO Xiaofei HU Ping SHI Wanting LI Wenyan NIE Fang▲ |
| Department of Thoracic Oncology, Baotou Tumor Hospital, Inner Mongolia Autonomous Region, Baotou 014030, China |
|
|
|
|
Abstract Objective To investigate the clinical study of Anlotinib combined with Irinotecan in the treatment of extensive small cell lung cancer (SCLC) after Etoposide + Cisplatin (EP) regimen. Methods A total of 80 patients with SCLC who progressed after EP regimen treatment admitted to Baotou Tumor Hospital of Inner Mongolia Autonomous Region from July 2020 to June 2022 were selected as the study objects. Random number table method was used to divide them into study group and control group, with 40 patients in each group. The study group was treated with Anlotinib combined with Irinotecan, while the control group was treated with Irinotecan, with a cycle of 21 days. The serum indexes of the two groups before and after four cycles of treatment were compared, and the occurrence of side effects and efficacy of the two groups were compared. Both groups were followed up for at least six months to observe the prognosis. Results After four cycles of treatment, matrix metalloproteinase 2, vascular endothelial growth factor, and transforming growth factor -β1 in two groups were lower than those before treatment, and those of study group were lower than those of control group, the differences were statistically significant (P＜0.05). The disease control rate of the study group was higher than that of the control group, and the difference was statistically significant (P＜0.05). There was no significant difference in the severity of side effects between the two groups (P＞0.05). The progression-free survival time (PFS) and overall survival time (OS) of the study group were longer than those of the control group (P＜0.05). Conclusion Anlotinib combined with Irinotecan has better clinical effect on patients with extensive SCLC after the progression of EP regimen than Irinotecan alone, and has a certain effect on prolonging PFS and OS.
|
|
|
|
|
|
[1] Rudin CM，Brambilla E，Faivre-Finn C，et al. Small-cell lung cancer [J]. Nat Rev Dis Primers，2021，7（1）：3.
[2] Wang Y，Zou S，Zhao Z，et al. New insights into small-cell lung cancer development and therapy [J]. Cell Biol Int，2020， 44（8）：1564-1576.
[3] Zugazagoitia J，Paz-Ares L. Extensive-Stage Small-Cell Lung Cancer：First-Line and Second-Line Treatment Options [J]. J Clin Oncol，2022，40（6）：671-680.
[4] Ganti AKP，Loo BW，Bassetti M，et al. Small Cell Lung Cancer，Version 2.2022，NCCN Clinical Practice Guidelines in Oncology [J]. J Natl Compr Canc Netw，2021，19（12）：1441- 1464.
[5] 杨培，李强，王艳，等.安罗替尼三线治疗小细胞肺癌的临床研究[J].重庆医学，2021，50（S01）：256-258.
[6] 姬颖华，杨晓煜，王瑾，等.安罗替尼联合伊立替康方案二线治疗晚期复发难治性小细胞肺癌的临床疗效观察[J].新乡医学院学报，2021，38（4）：328-331.
[7] 吕艺华，赵子龙，黄革红，等.安罗替尼联合伊立替康二线治疗小细胞肺癌的临床疗效及安全性[J].天津医药，2021，49（4）：436-440.
[8] Thai AA，Solomon BJ，Sequist LV，et al. Lung cancer [J]. Lancet，2021，398（10299）：535-554.
[9] Freites-Martinez A，Santana N，Arias-Santiago S，et al. Using the Common Terminology Criteria for Adverse Events（CTCAE-Version 5.0）to Evaluate the Severity of Adverse Events of Anticancer Therapies [J]. Actas Dermosifiliogr（Engl Ed），2021，112（1）：90-92.
[10] 杨学宁，吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学，2004，4（2）：85-90，111.
[11] de Kock I，Mirhosseini M，Lau F，et al. Conversion of Karnofsky Performance Status（KPS）and Eastern Cooperative Oncology Group Performance Status（ECOG）to Palliative Performance Scale（PPS），and the interchangeability of PPS and KPS in prognostic tools [J]. J Palliat Care，2013，29（3）：163-169.
[12] 侯继院，祁佩红，王海霞，等.盐酸安罗替尼单药对广泛期小细胞肺癌的疗效及安全性[J].实用医学杂志，2021，37（19）：2565-2568.
[13] 张孟伟，卢红.应用安罗替尼治疗小细胞肺癌伴脑转移患者一例[J].国际肿瘤学杂志，，2021，48（2）：125-126.
[14] Chen P，Liu Y，Wen Y，et al. Non-small cell lung cancer in China [J]. Cancer Commun（Lond），2022，42（10）：937-970.
[15] Yin X，Li Y，Wang H，et al. Small cell lung cancer transformation：From pathogenesis to treatment [J]. Semin Cancer Biol，2022，86（Pt 2）：595-606.
[16] 龚耀，鞠立荣，张铁成.安罗替尼联合EP方案一线治疗广泛期小细胞肺癌的回顾性研究[J].实用肿瘤杂志，2022，37（6）：555-560.
[17] 王宁军，马银杰，高业博，等.盐酸安罗替尼二线治疗老年小细胞肺癌的有效性和安全性观察[J].中国医药，2021，16（9）：1325-1328.
[18] 徐红燕，王文静，姜秀，等.安罗替尼维持治疗广泛期小细胞肺癌的疗效及对患者血清CEC，ES水平的影响[J].南昌大学学报（医学版），2022，62（1）：61-65.
[19] 王静怡，董量，付浩宇，等.安罗替尼二三线治疗的广泛期小细胞肺癌患者预后分析[J].中国临床医生杂志，2021，49（1）：38-41.
[20] 金晨星，赵翌，刘基巍.安罗替尼在肺癌治疗中的研究进展[J].临床肿瘤学杂志，2022，27（5）：460-466.
[21] 柳影，程颖.伊利替康联合顺铂二线治疗耐药复发小细胞肺癌临床研究[C]//全国肺癌学术大会，2013：219.
[22] Torres-Durán M，Curiel-García MT，Ruano-Ravina A，et al. Small-cell lung cancer in never-smokers [J]. ESMO Open，2021，6（2）：100059.
[23] 龚萍，梁维君，史百高，等.小细胞肺癌住院病例生存情况与预后影响因素分析[J].实用预防医学，2014，21（4）：398-402.
[24] 李子明，唐晓春，陈智伟.伊立替康在广泛期小细胞肺癌化疗中的应用[J].肿瘤，2009，29（7）：696-699. |
|
|
|
